Shares of Bacterin International Holdings Inc. (AMEX: BONE) are recovering nicely after the stock plunged almost -26% last week after reporting a larger Q4 loss than Wall Street analysts had expected. The penny stock of BONE gained 9.50% to close up 21 cents at $2.42 as shares of Bacterin International try to get back to their year-to-date high of $3.54.
Last week, Bacterin International reported record 2011 revenue of $30.1 million, an increase of 96% over the previous year. BONE’s operating loss for 2011 fell -25% to $6.5 million. Shares in the Amex listed penny stock dropped 87 cents, -25.82%, on the news since analysts were expecting a larger operating loss decrease greater than the reported $6.5 million.
Subscribe today and get our next stock alert delivered to your inbox FREE.
Volume on the penny stock has a 5-Day Average Volume of 749,213.
RSI on BONE has taken a turn from the oversold level.
Chairman and CEO of Baterin International, Guy Cook, commented on the earnings results saying that while BONE’s full year gross margin dropped to 70% mainly because of increased discounting on stocking purchase orders and non-recurring adjustments and increased reserves, BONE is poised for overall operating margins to increase considerably as the company gains operating leverage from its sales force and largely established infrastructure.
View the full BONE earnings report here.
Bacterin International is a developer, manufacturer and marketer of biologics products that optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth through BONE ‘s proprietary methods. Visit the BONE website for for details.
Bottom Line: The drop in share price in the penny stock was clearly based on earnings results which, although positive, were just not good enough for those who are paid to invest other people’s money. On the other hand, Bacterin International is obviously moving into the right direction which could make the current stock price a bargain for those willing to go long on BONE stock.